SEC Stock Data Quick Answer Xenon Pharmaceuticals Inc. reported Long-Term Debt of $10.89 million for fiscal year 2019. Xenon Pharmaceuticals Inc. Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2019 $10.89M -27.5% 2018 $15.01M +146.0% 2017 $6.10M — Quarterly Long-Term Debt Quarter Ending Long-Term Debt YoY QoQ December 31, 2019 $10.89M -27.5% -7.6% September 30, … Read more
Quick Answer Xenon Pharmaceuticals Inc. reported Cash and Equivalents of $199.16 million for fiscal year 2025. Xenon Pharmaceuticals Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $199.16M +39.6% 2024 $142.71M -4.0% 2023 $148.64M +159.7% 2022 $57.24M -67.4% 2021 $175.69M +290.3% 2020 $45.01M +81.8% 2019 $24.75M -63.5% 2018 $67.75M … Read more
Quick Answer Xenon Pharmaceuticals Inc. reported Total Assets of $633.16 million for fiscal year 2025. Xenon Pharmaceuticals Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $633.16M -20.7% 2024 $798.14M -17.3% 2023 $964.80M +27.9% 2022 $754.15M +31.8% 2021 $572.01M +202.4% 2020 $189.19M +28.1% 2019 $147.70M +20.6% 2018 $122.43M +165.4% 2017 $46.12M … Read more
Quick Answer Xenon Pharmaceuticals Inc. reported Diluted EPS of $4.36 per share (loss) for fiscal year 2025. Xenon Pharmaceuticals Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$4.36 -44.9% 2024 -$3.01 -10.3% 2023 -$2.73 -32.5% 2022 -$2.06 -16.4% 2021 -$1.77 -118.5% 2020 -$0.81 +50.3% 2018 -$1.63 +5.2% 2017 -$1.72 -16.2% … Read more
Quick Answer Xenon Pharmaceuticals Inc. reported Net Income of -$345.91 million for fiscal year 2025. Xenon Pharmaceuticals Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$345.91M -47.6% 2024 -$234.33M -28.5% 2023 -$182.39M -45.5% 2022 -$125.37M -58.9% 2021 -$78.88M -173.5% 2020 -$28.84M +30.7% 2019 -$41.59M -20.6% 2018 -$34.50M -12.4% 2017 -$30.70M … Read more
Quick Answer Xenon Pharmaceuticals Inc. reported Revenue (ASC 606) of $311.0 thousand for fiscal year 2017. Xenon Pharmaceuticals Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2017 $311.0K — Quarterly Revenue (ASC 606) Quarter Ending Revenue (ASC 606) YoY QoQ September 30, 2017 $264.0K — — The most recent … Read more
Quick Answer Xenon Pharmaceuticals Inc. reported Total Revenue of $311.0 thousand for fiscal year 2017. Xenon Pharmaceuticals Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2017 $311.0K -82.8% 2016 $1.80M -88.4% 2015 $15.58M -45.1% 2014 $28.37M +3.7% 2013 $27.36M +91.2% 2012 $14.31M — Quarterly Total Revenue Quarter Ending Total Revenue YoY … Read more
Quick Answer Xenon Pharmaceuticals Inc. reported Total Revenue of $311.0 thousand for fiscal year 2017. Xenon Pharmaceuticals Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue — — — — — — Revenue (ASC 606) — — — — — — Net Income -$345.91M-47.6% -$234.33M-28.5% -$182.39M-45.5% -$125.37M-58.9% -$78.88M-173.5% -$28.84M+30.7% … Read more
Quick Answer XCEL ENERGY INC reported Shares Outstanding of 623.60 million shares for fiscal year 2025. XCEL ENERGY INC Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 623.60M +8.6% 2024 574.37M +3.5% 2023 554.94M +1.0% 2022 549.58M +1.0% 2021 544.03M +1.2% 2020 537.44M +2.5% 2019 524.54M +2.0% 2018 514.04M +1.0% 2018 … Read more
Quick Answer XCEL ENERGY INC reported Operating Income of $2.58 billion for fiscal year 2025. XCEL ENERGY INC Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 $2.58B +8.3% 2024 $2.39B -3.8% 2023 $2.48B +2.2% 2022 $2.43B +10.2% 2021 $2.20B +4.1% 2020 $2.12B +0.6% 2019 $2.10B +7.1% 2018 $1.97B -11.6% 2017 $2.22B … Read more